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Abstract  
Acute lymphoblastic leukemia (ALL) is a hematological malignant disease characterized by an enhanced self-renewal 
ability of precursor lymphoid cells whose cell division takes more time than their normal counterparts. 
 ALL occurs most between 2 to 5 years of age and during the sixth decade of life. There is a strong relationship between 
the time ALL occurrence in children and the genetic abnormalities which are identified by the rate of leukemic 
concordance between identical twins. 
About 90% of ALL cases do not have a clear etiological mechanism. Genetic syndromes, polymorphic variants genes, 
germline mutations, and some environmental factors are responsible for less than 10% of ALL predisposition but the 
pathogenesis mechanism of ALL is not identified precisely. 
Here we review the recent findings and earlier studies about the pathogenesis of acute lymphoblastic leukemia and its 
incidence. This article also summarizes the identification of predictive factors for ALL and options available to predict 
disease recurrence. 
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Leukemia is one of the most important human 
challenges worldwide, which causes physical 
problems. Acute Lymphoblastic Leukemia (ALL) is a 
malignant disease on B- or T-cell lineage lymphoid 
progenitor (1, 2). Also, ALL can occur at any age in 
both children and adults, with the most incidence 
between the age of 2 to 5 years or in infants (3, 4). 
Pediatric ALL is an example of successful 
improvement in chemotherapy regimens and their 
survival probability has increased from 77% in the three 
past decades (5), up to 90% (6). The occurrence of 
relapse in ALL is high in adults (7). Chromosomal 
abnormalities and imperfect genes are very important 
factors in the evaluation of leukemia. The four common 
chromosomal abnormalities in pediatric ALL including 
t(12;21)(p12;q22)/ETV6-RUNX1, 
t(1;19)(q23;p13)/TCF3-PBX1, t(9;22)(q34;q11)/BCR-
ABL and t(4;11)(q21;q23)/MLL-AF4 (8) along with 
gene mutation in lymphoid differentiation regulator 
proteins e.g. Pax5 lead to promotion of ALL. The exact 
pathogenetic mechanisms in the development of acute 
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lymphoblastic leukemia are unknown. Only some 
cases are genetic syndromes, such as Down syndrome, 
Bloom’s syndrome, ataxia-telangiectasia, and 
Nijmegen breakage syndrome (9). In ALL, 
extramedullary localizations  in the central nervous 
system (CNS), lymph nodes, gonads, spleen or liver 
can occur (10). 
The aim of this study is to review the 
pathogenesis, chromosomal abnormalities, and 
epidemiology of ALL in children and the rate of 
relapse in adults which can help improve its diagnosis 
and treatment in patients. 
Incidence 
ALL is the proliferation and accumulation of 
lymphoid progenitor cells in the bone marrow and 
other tissues (11). The number of new cases and 
deaths in ALL patients diagnosed each year from 2012 
to 2015 increased in USA (12, 13). Patients, out of 
whom 60 %are people younger than 20 years of age, 
are mostly children. (3, 14-16).  The pediatric 
oncology group has reported survival in 85% to 95% 
of low-risk ALL patients in 2006 to 2009 (17). The 
incidence of childhood ALL is about 4–5 cases per 
100,000 children (18). In Mexico, the Popular Medical 
Insurance (PMI) reported an incidence of 62.5 cases 
per one million/year (19). B-cell acute lymphoblastic 
leukemia (B-ALL) is observed in 50% of patients 
(20), Philadelphia chromosome (Ph)–positive ALL in 
50% to 60% of patients (21, 22), and T-cell acute 
lymphoblastic leukemia (T-ALL)in 50% to 60% of 
patients (23). Acute lymphoblastic leukemia report of 
osteoporosis was observed in bone marrow more than 
25% blasts and leukopenia (24). The two major skeletal 
complications of leukemia are osteoporosis and 
avascular necrosis (25). A bone mineral accumulation 
process happened during the period corresponding to 
the onset of most childhood ALLs (26). Among the 
complications, musculoskeletal pain, disturbed gait, 
fractures, kyphosis, lordosis, and growth failure have 
been described. Pathological fractures and vertebral 
collapses secondary to severe osteopenia (leukemic 
osteopathy) may occur (27). In the childhood cancer 
study, long-term had an incidence of 73% chronic 
health conditions and mortality that was 11 times (28-
30). Cardiovascular toxicities, including 
cardiomyopathy, coronary artery disease, and 
arrhythmias are among the most common serious 
adverse events (31, 32). According to national cancer 
institute in Brazil, between 25% to 35% of all cancer 
types represent leukemia, and acute lymphoblastic 
leukemia is the most common between 0 to 14 years of 
age (33). The global estimated incidence of B-ALL is 
around 1 to 5 per 100,000 persons per year (34). 
Risk factors 
Genetic Syndromes  
The precise pathogenetic events leading to the 
development of ALL are unknown. Down syndrome, 
Bloom syndrome, ataxia-telangiectasia mutated 
(ATM), and Nijmegen breakage syndrome is the 
genetic syndromes that may occur in ALL (35-38), an 
estimated frequency of specific genotypes of ALL in 
children and adults are shown in Table 1 (39). Down 
Table1. Estimated Frequency of Specific Genotypes of ALL in Children and Adults 
Abnormality Children (%) Adults (%) 
Hyperdiploidy >50 chromosomes 25 7 
Hypodiploidy <45 chromosomes 1 2 
t(12;21) TEL-AML1 22 2 
t(8;14),t(2;8), t(8;22) MYC 2 4 
t(1;19) E2A-PBX1 5 3 
t(9;22) BCR-ABL 3 25 
t(4;11),t(11;19), t(9;11) MLL rearrangements 8 10 
Others 22 23 
HOX11L2 5q35* 2.5 1 
LYL1 19p13* 1.5 2.5 
TAL1 Ip32* 7 12 
HOX11 10q24* 0.7 8 
MLL-ENL* 0.3 0.5 
*Abnormalities T-cell ALL 
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syndrome is a heterogeneous disorder in ALL patients, 
including subtypes recognized with identical genetic 
abnormalities found in people, such as hyperdiploidy 
greater than 50 and [ETV6-RUNX1]t(12;21) (40, 41). 
CRLF2 dysregulation is found in approximately   60% 
of sporadic pediatric DS-ALL patients, which is an 
indicating factor in the development of DS subtype 
(42). The study showed that fusion and activation of 
P2RY8-CRLF2 with JAK mutations are observed in 
half of ALL patients with Down Syndrome (43, 44). 
Also, other genetic events including IKZF1 deletion 
have been found in ALL with Down syndrome (45-
47). Patients of ATM (ataxia-telangiectasia mutated) 
of the specific T-cell phenotype are at greater risk of 
leukemia than lymphoma (48). Overall, pathogenetic 
disorders cause acute lymphoblastic leukemia in 
population. 
 Environmental factors 
 The environmental factors that cause ALL 
include ionizing radiation, utero exposure to ionizing 
radiation, postnatal exposure to ionizing radiation, 
nonionizing radiation, alcohol cigarette and illicit drug 
use.  
Ionizing radiation. A case-control study has 
recognized that 1 percent of leukemia is a result of a 
slight increase in exposure to ionizing radiation (49, 
50). Ionizing radiation is one of the few exposures for 
which the causal relationship with childhood leukemia 
has been established (51, 52). Ionizing radiation 
exposure can cause leukemia during preconception, 
pregnancy, or the postnatal period.  
 In Utero exposure to ionizing radiation. In 
utero exposure to diagnostic x-rays does not decrease 
the risk of ALL, although there is a positive 
correlation with the number of exposures(53). A lot of 
studies have attempted to determine the effect of 
radiation exposure in utero and development of 
leukemia related to the atomic bomb exposures at the 
end of World War two in Japan, the Chernobyl 
(Russia) accident. Increase in risk of childhood 
leukemia as a result of the atomic bomb has yet been 
shown (53, 54). 
Postnatal exposure to ionizing radiation. In 
second world war, atomic bomb blasts increased the 
risk of childhood leukemia, similar to radiotherapy for 
benign diseases in postnatal exposure (55). Although 
to date, children who were exposed to Chernobyl 
accident have shown no increased risk of leukemia (56, 
57). The study found no significant risk of ALL, 
although three or more were exposed to radiation (58).  
Nonionizing radiation. Many epidemiologic 
studies have been conducted to determine the link 
between an exposure to nonionizing Electromagnetic 
Fields (EMFs) and childhood leukemia (59-61). 
Moreover, research on animals with exposure to higher 
levels of EMFs than humans haven’t shown increased 
hematopoietic neoplasm (62). Therefore, no significant 
increased risk of ALL was found based on EMF levels 
for mother during pregnancy (63).  
Alcohol, cigarette, and illicit drug use. Studies 
have shown an increased risk of childhood leukemia, 
especially among young children, associated with 
maternal alcohol consumption during pregnancy (64, 
65). Whether smoking before or during pregnancy is a 
risk factor for childhood leukemia is unknown (66). 
based on the  children's cancer group, maternal use of 
marijuana before or during pregnancy has been 
associated with childhood ALL (67). 
Conclusion 
In conclusion, the review showed the 
pathogenesis of acute lymphoblastic leukemia and its 
incidence. Furthermore, important factors such as 
genetic disorders and environmental factors causing  
ALL are described. Also, the prevalence of the disease 
in patients with genetic defects around the world has 
been mentioned. Thus, important factors in the 
pathogenesis of acute lymphoblastic leukemia patients 
were identified to improve health.  
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